Zai Lab Net Income Over Time
| ZLAB Stock | USD 17.22 0.02 0.12% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Zai Lab Performance and Zai Lab Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zai Lab. Anticipated expansion of Zai directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Zai Lab assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.90) | Revenue Per Share | Quarterly Revenue Growth 0.135 | Return On Assets | Return On Equity |
The market value of Zai Lab is measured differently than its book value, which is the value of Zai that is recorded on the company's balance sheet. Investors also form their own opinion of Zai Lab's value that differs from its market value or its book value, called intrinsic value, which is Zai Lab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zai Lab's market value can be influenced by many factors that don't directly affect Zai Lab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zai Lab's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zai Lab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Zai Lab's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Zai Lab and related stocks such as Legend Biotech Corp, Disc Medicine, and Ascentage Pharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LEGN | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | (2.8 M) | (101.6 M) | (266.4 M) | (403.6 M) | (446.3 M) | (518.3 M) | (177 M) | (159.3 M) | (167.3 M) |
| IRON | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (36 M) | (46.1 M) | (76.4 M) | (109.4 M) | (98.4 M) | (103.3 M) |
| AAPG | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (118.5 M) | (345.3 M) | (1.5 B) | (677.6 M) | (782.4 M) | (882.9 M) | (925.6 M) | (405.4 M) | (364.9 M) | (383.1 M) |
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (49.3 M) | (49.7 M) | (85 M) | (131.8 M) | (131.6 M) | (165.8 M) | (246.3 M) | (221.7 M) | (210.6 M) |
| IDYA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (34.3 M) | (38.4 M) | (32.3 M) | (47.5 M) | (54.8 M) | (113 M) | (274.5 M) | (247 M) | (234.7 M) |
| CNTA | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (10.7 M) | (381.9 M) | (216.2 M) | (151.1 M) | (235.8 M) | (212.2 M) | (222.8 M) |
| XENE | (12 M) | (12 M) | (4.3 M) | 12 M | 13 M | (15.8 M) | (23 M) | (30.7 M) | (34.5 M) | (41.6 M) | (28.8 M) | (78.9 M) | (125.4 M) | (182.4 M) | (234.3 M) | (210.9 M) | (200.4 M) |
| CDTX | (792 K) | (792 K) | (792 K) | (1.3 M) | (11.9 M) | (32.2 M) | (48.2 M) | (55.7 M) | (59 M) | (41.1 M) | (72.1 M) | (43.9 M) | (29.8 M) | (22.9 M) | (169.8 M) | (152.8 M) | (145.2 M) |
| TARS | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (4.7 M) | (26.8 M) | (13.8 M) | (62.1 M) | (135.9 M) | (115.6 M) | (104 M) | (98.8 M) |
| APGE | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (84 M) | (182.1 M) | (163.9 M) | (155.7 M) |
Zai Lab and related stocks such as Legend Biotech Corp, Disc Medicine, and Ascentage Pharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Zai Lab financial statement analysis. It represents the amount of money remaining after all of Zai Lab operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Zai Lab | ZLAB |
| Classification | Cancer Fighters |
| Business Address | Building B, Pudong, |
| Exchange | NASDAQ Exchange |
USD 17.22
Check out Zai Lab Performance and Zai Lab Correlation. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Zai Lab technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.